Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization … (NCT07567313) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy
166 participantsStarted 2026-04-20
Plain-language summary
This study intends to carry out prospective, randomized controlled clinical trials in many centers across the country to compare the efficacy and safety of immunotherapy after standard first-line chemotherapy or immunotherapy combined with interventional bronchial artery chemoembolization for stage IV lung squamous cell carcinoma.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Squamous cell carcinoma of the lung confirmed by histology or cytology;
✓. According to the TNM staging system of the 9th edition of American Cancer Association, it was assessed as stage IV.
✓. Has received standard first-line chemotherapy immunotherapy for 4\~6 cycles, and achieved partial remission or disease stability according to the efficacy evaluation of RECIST1.1;
✓. The patient is 18-80 years old;
✓. ECOG PS score is 0-1;
✓. The main organ functions meet the following criteria: (1) Blood routine examination: hemoglobin (HB) ≥ 90g/L; Leukocyte (ANC) ≥ 3.0× 109/L; Neutrophils ≥ 1.5× 109/L; Platelet (PLT) ≥ 75× 109/L; (2) Biochemical examination: albumin (ALB)≥29g/L; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2uln; Total bilirubin (TBIL) ≤ 1.5 ULN; Creatinine ≤ 1.5 ULN;
✓. Patients and/or their families agree to participate in clinical trials and sign informed consent forms;
✓. No history of other malignant tumors;
Exclusion criteria
✕. There is epidermal growth factor receptor (EGFR) sensitive mutation or anaplasticlymphomakinase (ALK) gene translocation;
✕. Have a history of allergy to contrast agents or chemotherapy drugs;
✕. Received other anti-tumor treatments other than standard first-line chemotherapy immunotherapy;
What they're measuring
1
Progression-free survival
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
Trial details
NCT IDNCT07567313
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
✕. Arrhythmia with myocardial ischemia or myocardial infarction above grade II and poor control (including QTc interval ≥450ms for men and ≥ 470 ms for women);
✕. Coagulation function is seriously abnormal and cannot be corrected;
✕. Hypertension patients still have poor blood pressure control (systolic blood pressure \> \>160mmHg, diastolic blood pressure \> 100 mmhg) after antihypertensive drugs treatment;
✕. Pregnant or lactating female patients;
✕. Have a history of mental illness or psychotropic drug abuse;